Gyre Therapeutics, Inc. (GYRE) Key Metrics
GYRE valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $644.7M
- Enterprise value
- $714.9M
- P/E (TTM)
- —
- Forward P/E
- 188.7
- PEG ratio
- —
- Price / sales
- 5.9 10-yr median 11.7
- Price / book
- 7.3
- EV / EBITDA
- 131.0 10-yr median 68.1
- Dividend yield
- —
- Beta
- 4.74
GYRE key metrics, 2015–2025
Fiscal year ended December 31, 2025 · U.S. dollarsGYRE valuation Price multiples at each fiscal year-end price.
GYRE returns How much profit the business earns on the capital it uses.
GYRE per-share figures Results divided by the shares outstanding at year-end.
GYRE financial health Debt, liquidity and how easily interest is covered.
GYRE efficiency & capital use Working capital cycle and where the cash goes.
GYRE valuation history
GYRE returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GYRE debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GYRE cash returned to shareholders
GYRE price vs earnings per share
GYRE key metrics
2015–2025| 2025 | 2024 | 2023 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $728.5M | $1.24B | $1.69B | — | — | — | — | — | — |
| Enterprise value | $677.0M | $1.21B | $1.66B | — | — | — | — | — | — |
| P/E ratio | 144.9 | 102.4 | — | — | — | — | — | — | — |
| Price / sales | 6.2 | 11.7 | 14.9 | — | — | — | — | — | — |
| Price / book | 6.9 | 19.5 | — | — | — | — | — | — | — |
| Price / free cash flow | — | — | 97.7 | — | — | — | — | — | — |
| Price / operating cash flow | 721.2 | — | 65.3 | — | — | — | — | — | — |
| EV / sales | 5.8 | 11.5 | 14.6 | — | — | — | — | — | — |
| EV / EBITDA | 40.0 | 68.1 | 81.6 | — | — | — | — | — | — |
| EV / free cash flow | — | — | 95.8 | — | — | — | — | — | — |
| Earnings yield | 0.7% | 1.0% | −5.5% | — | — | — | — | — | — |
| Free cash flow yield | −0.0% | −0.5% | 1.0% | — | — | — | — | — | — |
| Share price at fiscal year-end | $7.06 | $12.10 | $25.69 | $94.65 | $102.15 | $118.35 | $204.60 | $146.25 | $704.25 |
| Per share | |||||||||
| Revenue per share | $1.13 | $1.03 | $1.72 | — | — | — | — | — | — |
| Earnings per share | $0.05 | $0.12 | −$1.41 | — | — | — | — | — | — |
| Operating cash flow per share | $0.01 | −$0.04 | $0.39 | — | — | — | — | — | — |
| Free cash flow per share | −$0.00 | −$0.07 | $0.26 | — | — | — | — | — | — |
| Cash per share | $0.51 | $0.26 | $0.51 | — | — | — | — | — | — |
| Book value per share | $1.03 | $0.62 | −$0.24 | — | — | — | — | — | — |
| Tangible book value per share | $0.98 | $0.60 | −$0.29 | — | — | — | — | — | — |
| Capex per share | $0.01 | $0.03 | $0.13 | — | — | — | — | — | — |
| Debt per share | $0.01 | $0.02 | $0.01 | — | — | — | — | — | — |
| Shares outstanding | 103.2M | 102.3M | 65.8M | — | — | — | — | — | — |
| Change in shares outstanding | +0.9% | +55.4% | — | — | — | — | — | — | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | 5.9% | 50.9% | — | −76.9% | −58.6% | −39.9% | −92.1% | −71.4% | −47.0% |
| Return on invested capital (ROIC) | 17.0% | — | — | — | — | — | −158.0% | −63.2% | −33.4% |
| Return on assets (ROA) | 3.4% | 10.0% | −79.7% | −57.4% | −49.4% | −36.6% | −55.6% | −31.5% | −21.2% |
| Return on tangible assets | 3.1% | 9.8% | −82.0% | −58.6% | −56.0% | −24.1% | −54.6% | −44.5% | −21.2% |
| Free cash flow margin | −0.2% | −6.4% | 15.3% | −264.1% | — | — | — | — | — |
| Income quality (OCF / net income) | 0.20 | −0.30 | — | — | — | — | — | — | — |
| Financial health | |||||||||
| Total debt | $939,000 | $1.6M | $409,000 | $1.6M | $1.8M | — | $5.1M | $19.4M | $33.7M |
| Cash & short-term investments | $52.4M | $26.7M | $33.5M | $79.4M | $76.9M | $120.1M | $32.4M | $17.1M | $32.5M |
| Net debt | −$51.5M | −$25.1M | −$33.1M | −$77.7M | −$75.1M | −$120.1M | −$27.4M | $2.3M | $1.2M |
| Debt / equity | 0.01 | 0.03 | — | 0.02 | 0.03 | — | 0.17 | 1.21 | 1.07 |
| Debt / assets | 0.01 | 0.01 | 0.00 | 0.02 | 0.02 | — | 0.13 | 0.51 | 0.49 |
| Net debt / EBITDA | −3.04 | −1.41 | −1.63 | — | — | — | — | — | — |
| Current ratio | 5.60 | 3.32 | 2.85 | 5.03 | 3.32 | 25.83 | 4.48 | 1.71 | 1.82 |
| Quick ratio | 5.04 | 2.99 | 2.64 | 5.03 | 3.32 | 25.83 | 3.87 | 0.82 | 0.92 |
| Interest coverage | — | — | — | — | — | — | — | — | -9.3 |
| Working capital | $84.1M | $45.3M | $37.2M | $71.7M | $67.2M | $119.2M | $30.4M | $15.6M | $30.9M |
| Invested capital | $54.5M | $38.2M | −$48.9M | −$1.6M | −$6.7M | −$182,000 | $3.4M | $18.4M | $32.7M |
| Tangible asset value | $137.6M | $96.7M | $10.8M | $76.1M | $68.3M | $119.9M | $30.8M | $16.1M | $31.4M |
| Net current asset value | $78.5M | $37.8M | −$45.4M | $70.7M | $65.8M | $119.0M | $30.4M | $15.5M | $30.6M |
| Graham number | $1.06 | $1.28 | — | — | — | — | — | — | — |
| Graham net-net per share | $0.59 | $0.24 | −$0.83 | — | — | — | — | — | — |
| Capital allocation | |||||||||
| Dividends paid | — | — | — | — | — | — | $4.0M | — | — |
| Share buybacks (net) | — | — | — | — | — | — | — | — | $82,000 |
| Capex / revenue | 1.0% | 3.0% | 7.6% | 1.3% | — | 6,266.7% | 2.3% | 117.3% | 15.5% |
| Capex / operating cash flow | 117.8% | — | 33.2% | — | — | — | — | — | — |
| Capex / depreciation | 0.48 | 1.97 | 7.71 | 1.93 | 0.44 | 2.52 | 0.13 | 1.20 | 0.58 |
| Stock-based compensation / revenue | 6.1% | 0.8% | 6.4% | 17.3% | — | 43,433.3% | 84.8% | 159.1% | 18.6% |
| R&D / revenue | 11.7% | 11.4% | 12.1% | 252.9% | — | 357,900.0% | 1,262.0% | 2,896.0% | 340.5% |
| SG&A / revenue | 73.7% | 69.6% | 66.8% | 77.2% | — | 205,900.0% | 981.6% | 2,321.3% | 548.2% |
| Efficiency | |||||||||
| Days sales outstanding | 103.5 | 79.4 | 54.2 | 159.5 | — | — | 9.9 | 239.2 | 102.6 |
| Days of inventory on hand | 556.3 | 498.9 | 337.1 | 0.0 | — | — | 26,137.6 | 920.9 | 2,070.3 |
| Days payables outstanding | 7.8 | 21.8 | 27.9 | 203.4 | 6,908.8 | 2,443.5 | 1,671.0 | 30.7 | 57.5 |
| Cash conversion cycle (days) | 651.9 | 556.5 | 363.3 | -43.8 | — | — | 24,476.5 | 1,129.4 | 2,115.4 |
| Receivables turnover | 3.53 | 4.60 | 6.74 | 2.29 | 0.00 | — | 37.02 | 1.53 | 3.56 |
| Payables turnover | 46.69 | 16.78 | 13.06 | 1.79 | 0.05 | 0.15 | 0.22 | 11.89 | 6.35 |
| Inventory turnover | 0.66 | 0.73 | 1.08 | 9,163.00 | — | — | 0.01 | 0.40 | 0.18 |
| Asset turnover | 0.80 | 0.87 | 0.97 | 0.22 | 0.00 | 0.00 | 0.03 | 0.01 | 0.03 |
| Average receivables | $33.0M | $23.0M | $16.8M | $9.2M | $15.0M | — | $27,500 | $261,500 | $492,000 |
| Average payables | $116,000 | $231,500 | $355,000 | $5.1M | $2.8M | $997,500 | $792,000 | $888,000 | $939,000 |
| Average inventory | $8.3M | $5.3M | $4.3M | $1,000 | — | — | $12.4M | $26.6M | $33.8M |
| Intangibles / total assets | 2.8% | 1.4% | 2.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from GYRE's annual financial statements (latest annual report filed March 13, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
GYRE valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Gyre Therapeutics traded at 144.9 times earnings. Gyre Therapeutics earned a return on equity of 5.9% and a return on invested capital of 17.0% in fiscal 2025. It ended the year with $0.9 million of debt and $52.4 million in cash and short-term investments, a net cash position of $51.5 million.
See the GYRE income statement, the GYRE chart for price history, or the GYRE stock overview for the latest quote and news.
GYRE key metrics FAQ
What is Gyre Therapeutics's P/E ratio?
Gyre Therapeutics traded at 144.9 times earnings at the end of fiscal 2025.
What is Gyre Therapeutics's EV/EBITDA?
Gyre Therapeutics's enterprise value was 40.0 times EBITDA at the end of fiscal 2025 (enterprise value $677.0 million, EBITDA $16.9 million); the current EV/EBITDA is 131.0.
What is Gyre Therapeutics's return on equity?
Gyre Therapeutics's return on equity (ROE) was 5.9% in fiscal 2025: net income of $5.0 million on average shareholders' equity of $84.7 million.
What is Gyre Therapeutics's ROIC?
Gyre Therapeutics's return on invested capital was 17.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Gyre Therapeutics have?
Gyre Therapeutics had total debt of $0.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is Gyre Therapeutics's free cash flow yield?
Gyre Therapeutics generated -$0.2 million of free cash flow in fiscal 2025, a free cash flow yield of −0.0% on its market value at year-end ($728.5 million).
What is Gyre Therapeutics's current ratio?
Gyre Therapeutics's current ratio was 5.60 at the end of fiscal 2025: current assets were 5.60 times current liabilities.